Zobrazeno 1 - 10
of 1 453
pro vyhledávání: '"GUSELKUMAB"'
Autor:
Richard B. Warren, Kerry Donnelly, Sandeep Kiri, Vanessa Taieb, Mahmoud Slim, Kyle Fahrbach, Binod Neupane, Marissa Betts, April Armstrong
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 11, Pp 3133-3147 (2024)
Abstract Introduction Biologic treatments have made complete skin clearance in moderate to severe plaque psoriasis a real possibility. Although clinical trials demonstrated the superiority of bimekizumab over secukinumab, adalimumab, and ustekinumab,
Externí odkaz:
https://doaj.org/article/1b8b5aa9d0874f258cc203e0740e4093
Autor:
Mario Valenti, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Andrea Carugno, Marco Campoli, Carlo G. Carrera, Francesca M. Gaiani, Davide Strippoli, Federica Mola, Angelo V. Marzano, Nicola Zerbinati, Anna Minuti, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 11, Pp 2987-2997 (2024)
Abstract Introduction Guselkumab, a human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown efficacy in psoriasis and psoriatic arthritis. However, long-term real-world data on its effectiveness in patients with inade
Externí odkaz:
https://doaj.org/article/fd8bd851d8bd47e3b07fbd568cfba933
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 11, Pp 2999-3015 (2024)
Abstract Introduction Poor persistence to biologics can result in suboptimal health outcomes and increased economic burden for chronic conditions, including psoriasis (PsO). In Japan, studies evaluating factors responsible for biologic treatment pers
Externí odkaz:
https://doaj.org/article/f3b55aa2815b4310af3c8fd391f93c4d
Autor:
Jeffrey R. Curtis, Atul Deodhar, Enrique R. Soriano, Emmanouil Rampakakis, May Shawi, Natalie J. Shiff, Chenglong Han, William Tillett, Dafna D. Gladman
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 6, Pp 1501-1517 (2024)
Abstract Introduction Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs)
Externí odkaz:
https://doaj.org/article/631e6dc4cc6a4bb893e0571db9fd29f2
Autor:
Philip Mease, Tatiana Korotaeva, Pavel Shesternya, Muza Kokhan, Anton Rukavitsyn, Dmitry Vasilchenkov, Mohamed Sharaf, Frédéric Lavie, Atul Deodhar
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 6, Pp 1551-1567 (2024)
Abstract Introduction There are limited data on the use of advanced therapies to treat psoriatic arthritis (PsA) in Russia. Guselkumab, an interleukin (IL)-23p19-subunit inhibitor, demonstrated efficacy in patients with PsA in the phase 3 DISCOVER-1
Externí odkaz:
https://doaj.org/article/45579ebd45974493ad26516b7a01fa05
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 4, Pp 1240-1243 (2024)
Abstract Pityriasis Rubra Pilaris (PRP) is a rare papulosquamous inflammatory dermatosis with variable clinical presentation and poorly understood pathogenesis that often poses diagnostic and therapeutic challenges. Data on currently available treatm
Externí odkaz:
https://doaj.org/article/d183d5cb5f3f4b8f9762619fb76b644c
Autor:
April W. Armstrong, Peter Foley, Yan Liu, Megan Miller, Rachel E. Teneralli, Anthony Bewley, Kenneth B. Gordon, Kim A. Papp, Chenglong Han
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2577-2589 (2024)
Abstract Introduction Treating plaque psoriasis (PsO) with guselkumab (GUS) promotes skin clearance and is associated with improvements in health-related quality of life (HRQoL), anxiety, and depression. It is unclear whether improvements in patient-
Externí odkaz:
https://doaj.org/article/2e1fbdbdc341498ebebba1f697824c23
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Background While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels
Externí odkaz:
https://doaj.org/article/a2c76ba7640d455ca324eab40eda0874
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Background Biologics are essential in treating psoriasis. In recent years, the pathogenesis exploration and development of new target drugs have provided a more complete evidence-based foundation for the biological treatment of psoriasis. This study
Externí odkaz:
https://doaj.org/article/55cb89d25e5040a687facf57c9e9cb9d
Autor:
Maryia Zhdanava, Timothy Fitzgerald, Dominic Pilon, Rachel E. Teneralli, Aditi Shah, Lilian Diaz, Patrick Lefebvre, Steven R. Feldman
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Purpose: Real-world data comparing long-term performance of interleukin (IL)-23 and IL-17 inhibitors in psoriasis are limited. This study compared treatment persistence and remission among patients initiating guselkumab versus IL-17 inhibitors.Method
Externí odkaz:
https://doaj.org/article/c8df4e1686614c7997eaa377e7d1cd36